DexCom Price Targets Adjusted to $95 and $87 as G7 CGM Drives Margin Growth
William Plovanic of Canaccord reduced DexCom’s 2026 price target from $99 to $95 while maintaining a Buy rating after Q4 results met expectations. Baird’s Jeff Johnson raised his target from $82 to $87 and Outperform rating, forecasting the 15-day G7 CGM to drive global margins and sensor coverage expansion.
1. Analyst Price Target Revisions
On February 13, Canaccord Genuity’s William Plovanic cut DexCom’s 2026 price target from $99 to $95 and kept his Buy rating. Later that day, Baird’s Jeff Johnson reaffirmed an Outperform rating on DexCom and lifted his price target from $82 to $87, implying nearly 20% upside.
2. Q4 Results and 2026 Outlook
DexCom’s fourth-quarter results and 2026 outlook matched analyst expectations, reflecting continued focus on product enhancements across the U.S. market to maintain leadership in continuous glucose monitoring systems.
3. Product Leadership and International Plans
Management expects the 15-day G7 sensor to become the flagship product driving margin expansion, while international efforts include tiered sensor offerings and strengthened insurance coverage to broaden CGM adoption worldwide.